A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors by Carter, Paul
Oncotarget71833www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 44
A novel DNA methylation score accurately predicts death from 
prostate cancer in men with low to intermediate clinical risk 
factors
Amar S. Ahmad1, Nataša Vasiljević1, Paul Carter2, Daniel M Berney3, Henrik Møller4, 
Christopher S. Foster5, Jack Cuzick1, Attila T. Lorincz1
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen 
Mary University of London, London, EC1M 6BQ, UK
2Centre for Molecular Pathology, Royal Marsden Hospital, Sutton, SM2 5PT, UK
3Molecular Oncology Centre, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK
4King’s College London, Cancer Epidemiology and Population Global Health Program, London, SE1 3QD, UK
5HCA International, Pathology Laboratories, London, WC1E 6JA, UK
Correspondence to: Attila T. Lorincz, email: a.lorincz@qmul.ac.uk
Keywords: prostate cancer, progression biomarkers, DNA methylation, CAPRA score, survival analysis
Received: August 12, 2016    Accepted: September 20, 2016    Published: September 30, 2016
ABSTRACT
Clinically aggressive disease behavior is difficult to predict in men with low 
to intermediate clinical risk prostate cancer and methylation biomarkers may be 
a valuable adjunct for assessing the management of these patients. We set to 
evaluate the utility of DNA methylation to identify high risk disease in men currently 
considered as low or intermediate risk. DNA was extracted from formalin-fixed 
paraffin-embedded transurethral prostate resection tissues collected during the years 
1990−96 in a watchful-waiting cohort of men in the UK. The primary end point was 
death of prostate cancer, assessed by reviewing cancer registry records from 2009. 
Methylation was quantified by pyrosequencing assays for six genes (HSPB1, CCND2, 
TIG1, DPYS, PITX2, and MAL) with established biomarker value in prostate cancer. 
A novel prognostic methylation score was developed by multivariate Cox modelling 
using the six methylation biomarkers in 385 men with low-and-intermediate clinical 
risk variables and its prognostic value compared to two previously defined clinically-
derived risk scores. Methylation score was the most significant variable in univariate 
and bivariate analysis in men with low-to-intermediate CAPRA risk score. When 
combined with CAPRA score the hazard ratio was 2.02; 95% confidence interval, 
1.40−2.92. For a methylation score sensitivity of 83% the specificity was 44%, while 
the maximum achieved sensitivity by CAPRA was 68% at a specificity of 44%. The 
derived methylation score is a strong predictor of aggressive prostate cancer that 
could have an important role in directing the management of patients with low-to-
intermediate risk disease. The estimated areas under the curve (AUC) at 10 years of 
follow-up were 0.62 (95% CI: 0.51, 0.70) and 0.74 (95% CI: 0.65, 0.82) for CAPRA, 
and combined (CAPRA + methylation) risk score (CRS) respectively.
INTRODUCTION
Current inability to distinguish biologically indolent 
prostate cancer from that which will progress poses the 
greatest problem when deciding appropriate clinical 
management strategies for this disease. Although diagnosis 
by PSA may offer better outcomes by early treatment, [1] 
lack of specificity encourages overtreatment of indolent 
disease [2]. Following diagnosis, prostate cancer patients 
are commonly categorized as low, intermediate, and high 
risk to aid management decisions. Tools such as CAPRA 
(Cancer of the Prostate Risk Assessment) score, [3] which 
combines baseline PSA level, Gleason score, age, and other 
clinical variables can provide some qualitative measure 
of a patient’s risk for progression. However, three of the 
strongest weighting variables in defining clinical scores, i.e. 
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T-stage, biopsy Gleason score, and malignancy ratio of the 
biopsy cores, are subjective, and prone to interpretational 
bias, and can dramatically overestimate or underestimate 
the actual risk classification in any given patient. The 
prognostic value of TMPRSS2:ERG, [4] oncotype DX 
prostate cancer assay, [5] four kallikreins panel [6] and 
cell cycle progression (CCP) score [7] have so far shown 
varying potential utility. However, a pressing need still 
exists to validate additional scores for clinical use as well 
as identify standardized quantifiable molecular biomarker 
assays, or optimal combinations of biomarkers to improve 
disease stratification and subsequent management.
DNA methylation exists in the human genome in 
complex patterns and is essential for normal development 
in higher organisms. Deregulation of methylation is 
a common event in carcinogenesis with abnormal 
methylation contributing to both the occurrence and 
progression of prostate cancer [8–10]. In a recent 
report, we demonstrated that changes in methylation of 
HSPB1, CCND2, TIG1, DPYS, and, MAL, had significant 
prognostic effects in multivariate Cox models where 
death from prostate cancer was the study endpoint 
[11]. In an additional matched case-control study using 
a subset of patients with low and intermediate Gleason 
score, methylation of the PITX2 gene was informative for 
identification of men at high risk of aggressive prostate 
cancer [12]. Here we propose a new risk stratification 
score utilizing the methylation levels of the six genes: 
HSPB1, CCND2, TIG1, DPYS, PITX2, and MAL, that 
enhance identification of men with aggressive cancer who 
would otherwise be considered of low or intermediate risk 
based on clinical variables. The new classifier allows a 
more robust classification to segregate men of low risk 
who can be safely followed by active surveillance from 
those who require active intervention.
RESULTS
Of 573 eligible patients, 385 men were grouped 
into low-and-intermediate-risk CAPRA scores, of which 
57 (14.8%) died from prostate cancer, 188 (48.8%) 
died of other causes, and 140 (36.4%) were alive at last 
follow-up (December 2009) (Supplementary Figure S1). 
The distribution of the candidate predictors is shown in 
Supplementary Table S1. 
Schoenfeld residuals demonstrated no violation 
of the assumption of proportional hazards in any tested 
variable, therefore a multivariate Cox proportional hazards 
model was fitted with the six genes in the 385 men with 
low-intermediate-risk CAPRA scores. A DNA methylation 
score was developed from the multivariate Cox model 
(Supplementary Figure S2), which has the following form:
Methylation score = 0.543*log(1 + HSPB1) + 
0.357*log(1 + CCND2) – 0.349*log(1 + CCND2*HSPB1) 
+ 0.354*log(1 + TIG1) + 0.230*log(1 + DPYS) + 
0.182*log(1 + PITX2) + 0.118*log(1 + MAL).
The interaction term of CCND2*HSPB1 was added 
to the model because combined methylation of both 
genes together was negatively associated with death from 
prostate cancer (Supplementary Figures S3 and S4).
Univariately, the methylation score was the 
strongest predictor of prostate cancer related death with a 
hazard ratio [HR] 2.72, p < 10−8 compared to the CAPRA 
score HR 1.62, p < 10−7 (Table 1). Also in a bivariate 
analysis, the methylation score was the strongest predictor 
with HR: 2.02, p < 10−3. No significant interaction was 
observed between methylation score, and CAPRA score. 
The methylation score showed a weak correlation to extent 
of disease (Spearman’s rho = 0.39) and CAPRA score 
(Spearman’s rho = 0.38) (Supplementary Figure S5). The 
associated p-values were 3.2e-15 and 5.2e-15 respectively.
In a sensitivity analysis, using Jackknife (leave-
one-out) resampling, the alternatively developed 
score using parameterwise shrinkage factors for 
Cox regression confirmed the strong performance of 
methylation score (Supplementary Table S2). A second 
sensitivity analysis, where an alternative imputation 
method was used to predict the probability of T-stage 
III values (Supplementary Figure S6) further confirmed 
that methylation score had strong prognostic value 
(Supplementary Table S3). A log-rank chi-square test was 
used to compare survival curves of three subsets; omitted 
samples (n = 146; death from prostate cancer = 36); 
samples without missing values (n = 333, death from 
prostate cancer = 94), and samples with missing T-stage 
(n = 240, death from prostate cancer = 67). The Kaplan-
Meier curves of the three groups overlap (data not shown), 
suggesting that there is no subset difference in survival 
(log-rank chi-square test = 1.16, d.f. = 2, and p = 0.56).
The estimated areas under the curve (AUC) at 10 
years of follow-up were 0.62 (95% CI: 0.51, 0.70), 0.71 
(95% CI: 0.62, 0.80), and 0.74 (95% CI: 0.65, 0.82) 
for CAPRA, methylation, and combined (CAPRA + 
methylation) risk score (CRS) respectively (Figure 1). A 
bootstrap test with B = 1000 was performed to compare 
the AUCs of the CAPRA score and the CRS [13]. A 
statistically significant difference was observed between 
the AUC of CAPRA and CRS (p = 0.01). The optimum 
cut-off value for the methylation score was 2.34 and 
yielded 85% sensitivity and 39% specificity while the 
optimum cut-off CAPRA = 1, reached 68% sensitivity 
and 44% specificity. In comparison, at a cut-off (2.43) 
where methylation score reached the same specificity, a 
sensitivity of 83% was observed (Figure 1). 
Figure 2 presents the estimated absolute risk 
values from a Cox model with methylation score, and 
CAPRA score as predictors showing that the survival 
probabilities in all CAPRA groupings (CAPRA = 1–5) 
decrease as methylation score increases. Thus, rather 
than discrete survival probabilities based on CAPRA 
alone, introducing the CRS allows a further prediction 
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of death with methylation percentile. The Harrell c-index 
indicates a good discriminatory capacity of predictive 
performance of the methylation score (Table 2). We 
also performed a competing risks analysis using the 
Fine-Gray regression model [14, 15] for the cumulative 
incidences of the competing events, death from prostate 
cancer, death from other causes, and men still alive at 
censoring. We performed univariate, and bivariate analysis 
(Supplementary Table S4); the risk factors investigated 
were methylation -score and CAPRA score. Similar to 
the main analysis, the methylation score was the strongest 
independent predictor of death from prostate cancer in 
univariate and bivariate competing risk analyses.
DISCUSSION
This is the first study to establish the prognostic 
value of a DNA methylation score as a test for men with 
low-and-intermediate risk CAPRA-score prostate cancer 
which can be further combined with CAPRA into a 
powerful combined risk score. Our findings support the 
original hypothesis that methylation status of six selected 
index genes (HSPB1, CCND2, TIG1, DPYS, PITX2, 
and MAL) provides a novel, objective, and accurate 
prediction of death from prostate cancer in men clinically 
assessed as low to intermediate risk. The biomarkers in 
the classifier have different coefficients, consistent with 
varying individual effect sizes. HSPB1 and CCND2 are 
the two strongest and most predictive biomarkers and in 
combination with the other four genes gave a substantially 
higher sensitivity for aggressive behavior than was 
possible using CAPRA whatever threshold was used.
The methylation score was compared to the CAPRA 
score, comprising well-known clinical parameters: PSA 
level, Gleason score, T-stage, percentage of positive 
biopsy cores and age of the patient at diagnosis. 
Methylation score was the strongest predictor of prostate 
cancer related death univariately as well as in bivariate 
analyses, although both elements contributed additional 
independent information to the combined risk score. 
This suggests that measurements of methylation score 
and CAPRA represent independent aspects of disease 
Table 1: Univariate analysis for the methylation score and the CAPRA score (linear) as well as 
bivariate Cox analyses with the methylation score, and the CAPRA score (linear) as predictors
Univariate Bivariate model
marker HR (95% CI) Χ1² (p) HR (95% CI) Χ1² (p)
Methylation 2.72 (1.93, 3.83) 34.54 (4.2e–09) 2.02 (1.40, 2.92) 13.91 (1.9e–04)
CAPRA 1.62 (1.36, 1.91) 31.05 (2.5e–08) 1.40 (1.15, 1.69) 11.86 (5.7e–04)
Χ² (p) 46.26 (9.0e–11)
c-index (se) 0.74 (0.04)
Figure 1: Time-dependent ROC curves at ten-years of follow-up using the semiparametric monotone sequence 
efficient estimator for three prostate cancer risk scores. For the methylation (DNAme) score, 85% sensitivity and 39% specificity 
is indicated by a square. Sensitivities and specificities for CAPRA categories 1, 2, 3 and 4 are indicated with circles, where 1 achieved 
the maximum possible sensitivity of 68% and 44% specificity. If equalized to obtain the same specificity, the methylation score displayed 
sensitivity of 83% (triangle). The solid circle presents the optimum reached sensitivity of 87% and specificity of 45% for the combined risk 
score (CRS). The confidence intervals of AUC are based on 1000 bootstrap replicates.
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aggressiveness and both are required to improve the 
accuracy of prognosis. Therefore, patients managed by 
watchful-waiting or active surveillance can have the 
benefit of significant pre-treatment prognostic information 
from the methylation score.
The novelty of our work is underpinned by accurate 
measurement of methylation in a common set of well-
annotated clinical specimens from a large retrospective 
cohort with long follow-up. Furthermore, the risk of 
overfitting was minimized by keeping the gene panel small, 
thus reducing problems that often occur in studies with 
microarrays and deep sequencing of thousands of genes in 
small sample sets. The large size of Transatlantic Prostate 
Group (TAPG) cohort and a follow-up exceeding 10 years 
are two major strengths of our study. The TAPG cohort 
provides information on death from prostate cancer in a 
wide population from a country where PSA surveillance 
was available in a developed health service. This supports 
our ability to identify patients who would do well or poorly 
long-term with conservative management in a broader 
context than would be possible with many contemporary 
cohorts that use biochemical recurrence as this is a 
weaker surrogate end point. Our results suggest that the 
methylation score could accurately predict prostate cancer 
related death with a Harrell’s c-index of 0.72, generally 
interpreted in the same way as an AUC, and it is plausible 
that extended studies may reveal additional methylation 
biomarkers to improve the overall performance.
Our methylation score is an objective multi- 
dimensional molecular classifier and is clearly distinct 
from a surrogate vectorial clinical classifier such as 
CAPRA score. It is also quite distinct from other 
molecular assessments such as the CCP score or Oncotype 
DX Prostate cancer assay [5, 7]. The established activities 
of DYPS, MAL, and TIG1 are consistent with tumor 
suppression [16–18] while CCND2, HSPB1 and PITX2 
are mainly oncogenic [19–21]. In prostate cancer, PITX2 
was earlier shown to be a prognostic biomarker of 
biochemical recurrence in which increased methylation 
was associated with reduced mRNA transcription 
[22, 23]. The DNA methylation classifier assesses aspects 
of epigenetic modification which may determine the 
behavioral phenotype of an individual man with prostate 
cancer. Primary prostate cancers occurring in individuals 
are typically genetically heterogeneous [24], so that the 
efficacy of the new classifier depends upon the biological 
relevance of the individual focus of cancer biopsied. 
While other reports have identified hypermethylation as 
a powerful modality with which to confirm the presence 
of prostate cancer [25], only the new classifier has the 
apparent ability to accurately predict which men have 
poor outcome within the group of low-to-intermediate 
clinical risk.
Although in current practice, TURP diagnosed 
cancers usually are small and confined to the transition 
zone, our TAPG TURP cohort contained a greater 
Figure 2: Estimated absolute risk values from a Cox model with combined risk score as predictors (black symbols) 
show that a patient with any given CAPRA score would be likely to get a more accurate risk stratification depending 
on the level of methylation (DNAme) of the six genes in the methylation score. The gray symbols show the estimated survival 
probabilities from a univariate Cox model if CAPRA score alone is used as a predictor.
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percentage of aggressive cancers due to the particular 
practice patterns of the 1990. Hence, it does not reflect 
the finer points of contemporary practice in the diagnosis 
or treatment of prostate cancer. However, objective 
evidence shows that the TAPG cohort is well suited to 
both biomarker discovery and validation e.g. the same 
set of specimens was used to validate the CCP score that 
has now become commercially available as a routine 
clinical test [7, 26]. Another limitation of our study is 
that death from prostate cancer was relatively rare in this 
clinically low risk group of men and larger cohorts are 
needed to fully characterize the value of the methylation 
score in identifying higher risk patients. Validation of the 
methylation score in contemporaneous cohorts diagnosed 
by use of needle biopsy is an obvious next step.
In conclusion we have shown that a novel DNA 
methylation classifier provides additional prognostic 
information both for men with localized prostate cancer 
and also for their managing clinicians who face difficult 
choices between active surveillance versus immediate 
and potentially aggressive therapy. If generally confirmed 
in other settings, the methylation score is likely to make 
a major contribution to the management of prostate 
cancer worldwide. Further validation studies are needed, 
especially for screen-detected cancers that are diagnosed 
by needle biopsy in situations where active surveillance 
without initial treatment is an ethical option. The new 
DNA methylation score can aid clinical decision making 
in patients with prostate cancer who with current 
risk assessment methods are misidentified as low or 
intermediate risk.
MATERIALS AND METHODS
Patients
The study cohort includes well-characterized men 
residing in Great Britain who did not receive any treatment 
for minimum six months following diagnosis of prostate 
cancer. Patients were excluded if they were treated by 
radical prostatectomy, hormones, radio- or chemotherapy, 
showed objective evidence of metastatic disease, had a 
PSA measurement above 100 ng/mL or died at or within 
six months of diagnosis. Original histological specimens 
from the diagnostic procedure were requested, collected, 
and diagnosis centrally reviewed by a panel of expert 
urological pathologists. Gleason scores were reassigned 
by use of a contemporary interpretation of the scoring 
system [27].
National ethical approval was obtained from 
the Northern Multicenter Research Ethics Committee 
followed by local ethics committee approvals from each 
of the collaborating hospital trusts [28].
Specimen characteristics
719 formalin-fixed paraffin wax-embedded (FFPE) 
transurethral resection of prostate (TURP) tissues from the 
TAPG cohort were included (Supplementary Figure S1, 
and Table 3). The material was used as described in detail 
in a previous study [28].
Assay methods
Methylation data from 367 patients was obtained 
from previous studies [11, 12]. Methylation measurements 
for HSPB1, CCND2, TIG1, DPYS, PITX2, and MAL were 
performed on bisulfite converted DNA from an additional 
352 patients as previously described [11, 12].
The number of included patients from the first and 
second group were 218 (57%) and 167 (43%) respectively. 
We have performed a statistical analysis to test for batch 
effect by comparing the Kaplan-Meier curves of the two 
groups. The two groups KM curves overlap, suggesting no 
subset difference in survival (log-rank chi-square test = 1.7 
and p-value = 0.195). Furthermore, a univariate Cox model 
was fitted with a binary variable (1st group and 2nd group) as 
predictor. The group variable was not statistically significant 
(LR test chi-square = 1.667, p-value = 0.197). This suggests 
no batch effect was observed in the analyzed data.
Study design
Men were included if they had clinically localized 
disease diagnosed by TURP from 1990–1996 inclusive, 
and were younger than 76 years at the time of diagnosis. 
The study median follow-up time was 11.36 years with 
IQR 6.20–14.72.
The CAPRA-score for each subject was computed, 
and 188 patients with high risk CAPRA scores (> 5) were 
Table 2: The predictive performance of methylation with respect to calibration and discrimination, 
using 5-fold cross-validation (repeated 100 times and averaged)
Calibration Slope Harrell’s c-index 
estimate (95% CI) 0.828 (0.604, 1.063) 0.678 (0.647, 0.708)
The cross-validated calibration slope (slope of predicted log hazard vs. true log hazard) was 0.83, indicating acceptable fit. 
The Harrell c-index was 0.68, indicating good discriminatory capacity. This c-index value of 0.68 from the internal validation 
is an honest estimate of internal validity, which penalizes for overfitting. The above table shows the average of 100 repeated 
values of the estimated calibration slope and estimated Harrell’s c-index with (α/2; 1−α/2) percentile confidence interval, 
where α = 0.05.
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excluded from the analysis with the rationale that these 
high risk men are not candidates for active surveillance, 
and will receive definitive treatment regardless of any 
additional molecular genetic information (Supplementary 
Figure S1). One patient with CAPRA = 0 (age 
49.95 years) was included as part of the CAPRA = 1 group. 
Study endpoints were compared for the CAPRA variables 
and for gene methylation measurements of the six genes. 
Sample size calculations were not done, this was a large 
study and we selected samples from all men available from 
the archives.
Statistical analysis 
The statistical methods were documented in a pre-
specified statistical analysis plan and laboratory testing 
was blinded from the clinical variables to minimize bias 
in the results. Cox proportional hazards models were 
used to analyze the effects of covariates on the primary 
endpoint, death from prostate cancer. Patients were 
censored on the date of last follow-up, or death from 
other causes. Schoenfeld residuals were examined to 
determine if Cox modelling was an appropriate analytical 
approach. The Spearman’s rank correlation was 
estimated between all variables and scores individually. 
Time-dependent receiver operator characteristic (ROC) 
curves were plotted at ten-year follow-up using the 
semiparametric monotone sequence estimator for the 
methylation score, CAPRA score, and the combined 
risk score (CRS). A relatively small span was chosen 
0.25*n−1/5, where n = 385 is the number of observations, 
[29] which yields only moderate smoothing to facilitate 
comparison of the nearest neighbor estimator. Prostate 
cancer survival probabilities at ten-years were predicted 
from fitted univariate Cox proportional hazards models. 
Five-fold cross-validation was done using the R-validate 
command. This was repeated 100 times to obtain an 
average optimism, which was subtracted from the final 
model fit indexes (e.g. c-index, and calibration slope) 
to obtain the overfitting-corrected estimates [30]. In 
a first sensitivity analysis, a parameterwise shrinkage 
analysis for factors of regression coefficients from the 
multivariate fitted Cox regression with methylation of 
the six genes and the interaction between CCND2 and 
HSPB1 was performed using a Jackknife (i.e. leave-one-
out resampling) analysis. An alternative methylation 
score was developed using the shrunken regression 
coefficients. In the second sensitivity analysis, the 
missing T-stage values were predicted by fitting a 
multivariate logistic regression with Gleason, PSA, 
Table 3: Overview of clinical and methylation variables in the entire TAPG patients (N = 719) and 
analyzed samples (n = 385) 
variable name variable CAPRA points N (%) n (%)
Gleason Score no pattern 4 or 5 0 375 (52.2%) 281 (73.0%)
 secondary pattern 4 or 5 1 123 (17.1%) 65 (16.9%)
 primary pattern 4 or 5 3 221 (30.7%) 39 (10.1%)
Clinical stage T1 or T2 0 356 (49.51%) 376 (97.7%)
 T3 1 78 (10.85%) 9 (2.3%)
 NA NA 285 (39.64%)  
PSA score (ng/mL) PSA ≤ 6 0 315 (43.8%) 244 (63.4%)
 6 < PSA ≤ 10 1 82 (11.4%) 60 (15.6%)
 10 < PSA ≤ 20 2 113 (15.7%) 54 (14.0%)
 20 < PSA ≤ 30 3 74 (10.3) 20 (5.2%)
 PSA > 30 4 116 (16.1%) 7 (1.8%)
 NA NA 19 (2.6%)  
Cancer in biopsy (%) Extent < 34% 0 461 (64.1%) 316 (82%)
 Extent ≥ 34% 1 255 (35.5%) 69 (18%)
 NA NA 3 (0.4%)  
Age at diagnosis Age < 50 0 2 (0.3%) 1 (0.3%)
 Age ≥ 50 1 717 (99.7%) 384 (99.7%)
Sample size   Total = 719 Analyzed = 385
CAPRA-score points are indicated for comparison.
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log(1 + Extent), age at diagnosis as predictors, and 
T-stage as the response variable with T1&T2 (n = 270, 
81%), and T3 (n = 63, 19%) in the 333 patients with data 
available for all clinical and methylation variables.
All applied statistical tests were two-sided, p < 0.05 
were considered significant. No adjustment for multiple 
comparisons was made. Analyses were performed in R 
version 3.2.3.
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